Executive SummaryReceives U.S. patent for monoclonal antibody-based therapeutic agents that localize at a tumor or infection site before becoming active. The products involve neutron capture therapy, in which boron compounds attached to the monoclonal antibodies are irradiated with attenuated neutrons to emit cytotoxic alpha particles.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.